The U.S. Food and Drug Administration has announced that Xanodyne Pharmaceuticals, Inc., the maker of prescription pain medications Darvon and Darvocet, has agreed to withdraw the medications from the U.S. market. The move comes after the results of an FDA study in which new clinical data shows the drug, which goes by the generic name propoxyphene, puts patients at risk of potentially serious or even fatal heart rhythm abnormalities. The FDA determined the new data shows the risks of the drug outweigh any benefits.
Propoxyphene is an opioid used to treat mild to moderate pain. First approved by the FDA in 1957, propoxophene is sold by prescription under various names both alone (Darvon) or in combination with acetaminophen (Darvocet). After safety concerns were raised in 1978, and again in 2009, the FDA formed an advisory committee to review available data. In July 2009, a boxed warning was added to the drug, alerting patients and health care professionals of the danger of overdose. At that time, the FDA also required Xanodyne to conduct a new safety study assessing unanswered questions about the effect of propoxyphene on the heart.
Results of the study show that even when taken at recommended doses, propoxyphene causes significant changes to the electrical activity of the heart. These changes can increase the risk for serious abnormal heart rhythms that have been linked to serious adverse effects, including sudden death.
We are investigating cases involving sudden death or hospitalization with an abnormal heart rhythm while taking either Darvocet or Darvon.
Lawyer: Chad Cook
Primary Contact: Tabitha Dean
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.